Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
GILD News
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating on April 25. Daina Graybosch’s rating is based...
Gilead Sciences ( ) First Quarter 2025 Results Key Financial Results Revenue: US$6.67b (flat on 1Q 2024). Net income: US$1.32b (up from US$4.17b loss in 1Q 2...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Friday. Shares of Skechers U.S.A., Inc. SKX fell sharply in to...
Analyst ratings
61%
of 31 ratingsMore GILD News
Gilead Sciences ( (GILD) ) has released its Q1 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors. Gilead Sciences, In...
Gilead Sciences, Inc. GILD released its first-quarter results after Thursday's closing bell. Here's a look at the details from the report. The Details: Gilead...
Gilead Sciences slipped 3% in after-hours trading after it reported sales that missed Wall Street estimates, though earnings came in better than expected. The...
As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, up from $100, as t...